Synedica Glow Skin 112mg

Synedica Glow Skin 112mg is a triple-peptide research formulation combining GHK-Cu, BPC-157, and TB-500 in a precision injection pen format. Synedica currently lists Glow Skin 112mg in its Cosmetic category with a stated 112mg total dose and 40 × 2.8mg doses.

The formulation brings together three peptides that have attracted research interest across peptide biology, tissue biology, extracellular-matrix research, cellular signaling, and skin-related research models.

What Is Synedica Glow Skin 112mg?

Synedica Glow Skin 112mg is a combination peptide formulation designed for research applications involving GHK-Cu, BPC-157, and TB-500.

The three components represent different areas of peptide research:

• GHK-Cu — a copper-binding peptide studied in skin and extracellular-matrix biology.
• BPC-157 — a synthetic peptide investigated primarily in preclinical biological research.
• TB-500 — a peptide associated with research into cellular and tissue biology.

Synedica lists Glow Skin 112mg as a Cosmetic product and identifies the formulation as an injection pen kit.

Synedica Glow Skin 112mg Formula

The Glow Skin formulation combines three research peptides:

GHK-Cu

GHK-Cu is a naturally occurring copper-binding peptide that has been studied extensively in relation to extracellular-matrix biology, collagen-related pathways, skin biology and cellular signaling.

Research involving GHK-Cu includes investigation of:

• Extracellular-matrix activity
• Collagen-related pathways
• Fibroblast biology
• Skin-cell research
• Copper-dependent cellular processes
• Tissue biology

BPC-157

BPC-157 is a synthetic peptide that has primarily been investigated in preclinical research.

Research interest surrounding BPC-157 includes:

• Tissue biology
• Cellular signaling
• Vascular biology
• Inflammatory pathways
• Gastrointestinal research models
• Repair-related biological pathways

Evidence from preclinical studies should not be interpreted as proof of established clinical benefits in humans.

TB-500

TB-500 is associated with research into peptide and tissue biology, including cellular migration and other biological processes.

Research areas may include:

• Cell migration
• Tissue biology
• Cellular signaling
• Vascular research
• Peptide biology
• Regenerative biology models

The combination of these three peptides makes Glow Skin 112mg particularly relevant to researchers studying multiple pathways involved in cellular and tissue biology.

Synedica Glow Skin 112mg Product Specifications

The current Synedica catalog lists the following product information:

Product: Synedica Glow Skin 112mg
Category: Cosmetic
Format: Injection pen kit
Total dose: 112mg
Listed doses: 40 × 2.8mg
Formulation: GHK-Cu + BPC-157 + TB-500
Research focus: Peptide, skin and tissue biology research

Always verify the current product label and manufacturer documentation for the exact formulation and packaging associated with a specific batch.

GHK-Cu Research

GHK-Cu is one of the best-known copper-binding peptides studied in skin and extracellular-matrix research.

Research has investigated its relationship with biological processes involving:

• Collagen
• Fibroblasts
• Extracellular matrix
• Skin-cell signaling
• Wound-related cellular models
• Copper metabolism

This makes GHK-Cu particularly relevant to laboratory research examining skin structure and cellular interactions.

BPC-157 Research

BPC-157 is a synthetic peptide that has generated interest in preclinical research.

Researchers have investigated BPC-157 in experimental models involving tissue biology, vascular responses, cellular signaling and inflammatory processes.

However, preclinical findings cannot automatically be translated into proven human therapeutic effects. This distinction is important when describing BPC-157 products for research purposes.

TB-500 Research

TB-500 is another peptide associated with tissue and cellular research.

Research interest includes biological processes such as cell migration and signaling pathways that may be relevant to tissue models.

As with BPC-157, research findings should be interpreted within the limitations of the available scientific evidence rather than presented as established human treatment outcomes.

Why Researchers Study the Glow Skin Combination

The main research interest in Synedica Glow Skin 112mg comes from combining peptides with different biological research profiles.

Skin Biology Research

GHK-Cu is particularly relevant to research involving extracellular-matrix biology, fibroblasts and skin-related cellular processes.

Tissue Biology

BPC-157 and TB-500 have been investigated in preclinical models involving tissue and cellular processes.

Peptide Combination Research

A multi-peptide formulation allows researchers to investigate different biological pathways within the same experimental framework.

Cellular Signaling

All three compounds have attracted research interest in cellular signaling and peptide-mediated biological processes, although their mechanisms and evidence bases differ.

Synedica Glow Skin 112mg Injection Pen

Synedica currently presents Glow Skin 112mg in an injection pen kit format. The catalog states a total dose of 112mg and 40 × 2.8mg doses.

The pen format provides a standardized product presentation for research applications. Exact handling, storage and laboratory procedures should be determined from the current product documentation and the requirements of the relevant research protocol.

Glow Skin 112mg Research Applications

Potential research areas associated with the individual components include:

• Skin biology
• Peptide research
• Extracellular-matrix research
• Collagen-related research
• Fibroblast research
• Cellular signaling
• Tissue biology
• Vascular biology
• Regenerative biology models
• Cosmetic science research

These are research areas rather than claims that the product has demonstrated therapeutic efficacy.

Synedica Glow Skin 112mg Quality and Verification

Synedica states that its products are supplied with product-verification features, including a scratch-off code intended to help authenticate products. Its current catalog also identifies Glow Skin 112mg as one of its newer Cosmetic products.

Researchers and distributors should review the product packaging, batch information and available analytical documentation before using any research material.

Important Research Notice

Synedica Glow Skin 112mg should be treated as a research and development product. It should not be represented as an approved cosmetic medicine, prescription treatment, or clinically proven anti-aging or tissue-repair therapy.

GHK-Cu, BPC-157 and TB-500 have different levels and types of scientific evidence. In particular, findings from laboratory and preclinical studies should not be presented as proof of safety or efficacy in humans.

This product page therefore focuses on the compounds, product specifications and research areas rather than making unsupported therapeutic claims.

Synedica Glow Skin 112mg Summary

Synedica Glow Skin 112mg is a triple-peptide formulation combining GHK-Cu, BPC-157 and TB-500. Synedica currently lists it in the Cosmetic category as an injection pen with a 112mg total dose and 40 × 2.8mg doses.

Its primary research relevance comes from the different biological areas associated with its three peptide components, including skin biology, extracellular-matrix research, cellular signaling and tissue biology.

For researchers searching for Synedica Glow Skin 112mg, GHK-Cu BPC-157 TB-500, or related peptide research terminology, this page provides product-focused information while maintaining a clear distinction between research applications and established clinical claims.